MARKET

RXRX

RXRX

RECURSION PHARMACEUTICALS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.91
-0.17
-1.53%
Opening 10:22 01/27 EST
OPEN
11.39
PREV CLOSE
11.08
HIGH
12.00
LOW
10.86
VOLUME
92.39K
TURNOVER
--
52 WEEK HIGH
42.81
52 WEEK LOW
10.35
MARKET CAP
1.84B
P/E (TTM)
-1.8208
1D
5D
1M
3M
1Y
5Y
Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 01/12 13:36
Recursion (RXRX) Inks Neuroscience and Oncology Deal With Roche
Zacks.com · 12/08/2021 16:28
SVB Leerink Maintains Outperform on Recursion Pharmaceuticals, Raises Price Target to $32
SVB Leerink analyst Mani Foroohar maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Outperform and raises the price target from $30 to $32.
Benzinga · 12/08/2021 09:40
Roche/Genentech spinal muscular atrophy treatment granted Orphan Drug designation
A monoclonal antibody under development from Roche (OTCQX:RHHBY) company Genentech was granted Orphan Drug designation for spinal muscular atrophy. The treatment is classified as a recombinant humanized IgG1-based monoclonal antibody which
Seekingalpha · 12/07/2021 23:23
Roche COVID antibody treatment tocilizumab approved by EMA
The European Medicines Agency ("EMA") has approved Roche's (OTCQX:RHHBY +0.1%) COVID-19 antibody treatment Actemra/RoActemra (tocilizumab). The regulator's Committee for Medicinal Products for Human Use recommended approval yesterday. The therapy is
Seekingalpha · 12/07/2021 18:04
Recursion Announces Collaboration With Roche And Genentech In Neuroscience And Oncology; Recursion To Receive $150M Upfront, Says Collaboration Could Yield $300M In Milestones And Royalties
 Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today
Benzinga · 12/07/2021 12:58
Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced a transformational collaboration with Roch...
PR Newswire · 12/07/2021 12:55
Roche Signs Machine-Learning Neuroscience Deal With Recursion
Bloomberg · 12/07/2021 12:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RXRX. Analyze the recent business situations of RECURSION PHARMACEUTICALS, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RXRX stock price target is 32.67 with a high estimate of 37.00 and a low estimate of 28.00.
High37.00
Average32.67
Low28.00
Current 10.91
EPS
Actual
Estimate
-1.70-1.27-0.85-0.42
Q2 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 85
Institutional Holdings: 54.45M
% Owned: 32.22%
Shares Outstanding: 168.99M
TypeInstitutionsShares
Increased
42
7.11M
New
18
1.38M
Decreased
11
456.33K
Sold Out
7
63.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.52%
Pharmaceuticals & Medical Research
+1.75%
Key Executives
Non-Executive Chairman/Independent Director
R. Martin Chavez
President/Chief Operating Officer
Tina Larson
Chief Executive Officer/Director
Christopher Gibson
Chief Financial Officer/Primary Contact
Michael Secora
Chief Human Resource Officer
Heather Kirkby
Chief Technology Officer
Benjamin Mabey
Chief Scientific Officer
Sharathchandra Hegde
General Counsel
Louisa Daniels
Other
Ramona Doyle
Other
Mason Victors
Other
Shafique Virani
Independent Director
Zachary Bogue
Independent Director
Blake Borgeson
Independent Director
Terry - Ann Burrell
Independent Director
Zavain Dar
Independent Director
Robert Hershberg
Independent Director
Dean Li
No Data
  • All
  • Financials
  • Insiders
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company uses Recursion Operating System (Recursion OS), a multi-layer system for generating, analyzing and deriving insights from biological and chemical datasets. It consists of three parts: Infrastructure Layer, The Recursion Data Universe and The Recursion Map. Its programs include REC-4881, REC-3599, REC-2282, REC-994, lead molecules for the treatment of C. difficile Colitis, lead molecules for the treatment of Neuroinflammation, lead molecules for the treatment of Batten Disease and lead molecules for the treatment of CMT2A.

Webull offers kinds of Recursion Pharmaceuticals Inc stock information, including NASDAQ:RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.